Phosphagen. Share Discussion Threads

[spaceparallax] 09/10/2007 10:06

The Nestle deal is beginning to look very promising.

[rambutan2] 08/10/2007 16:04

thankyou collins stewart!


for anyone who hasn't, the 30 august interview with harry rosen is worth a listen...

[rambutan2] 08/10/2007 01:22

expect last week's "missing" rns to appear later his morning. as previously, blame our nomad (cs) and not psg.

[hopeless698] 05/10/2007 08:01

This was tipped by the Shares magazine as one of the Top performers for the future. I totally agree, don't like to set timescales and targets but this is an absolute beauty!

[donaferentes] 04/10/2007 18:20

another solid step along the road - ltbh, bottom draw for my old age.

[ladybird1] 04/10/2007 15:29

Many thanks, suesean. I had been thinking of adding a bit (ony 10k, but it adds up) & this tipped the scales & have now done so. There can't be many 'fledgling' companies with both the breadth & heavyweight support of PSG.

[suesean1] 04/10/2007 14:22

News out again, again no RNS.

Nestlé Nutrition and Phosphagenics to commence Phospha E® phase 2 clinical trial







Phosphagenics Limited (ASX: POH; AIM: PSG; OTCQX: PPGNY) and Nestlé Nutrition (Nestlé) today announced that they will jointly commence a phase 2 human clinical trial in Australia to establish the efficacy of Phosphagenics' Phospha E® in the management of metabolic syndrome.



Ethics approval has been obtained to conduct the double-blind phase 2 clinical trial which will commence shortly.



Metabolic syndrome is characterised by a group of risk factors that increase the risk of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls, such as stroke. The American Heart Association estimates that 47 million U.S. residents have metabolic syndrome.



Dr Esra Ogru, Executive Vice President Research & Development at Phosphagenics, said: "It is very rewarding to see Phospha E® progress down the clinical trial path after years of pre-clinical testing. We have reached a very exciting stage of the development of this product and are delighted to be aligned with the world's largest nutrition company as our partner."



Nestlé will fund the phase 2 clinical trials and will be granted a worldwide exclusive license for the use of Phospha E® in medical foods, while Phosphagenics will manufacture and supply Phospha E® to Nestlé. The final commercial arrangements are expected to be completed by the end of this year.



This new collaboration builds upon two pre-clinical dose response trials performed by Nestlé and Phosphagenics in 2006. The results of trials confirmed that, when given orally, Phospha E® significantly reduced many of the key biomarkers associated with metabolic syndrome, inflammation and cardiovascular disease

[suesean1] 28/9/2007 16:06

Start taking nitice, RAM, another 95,000.

[spaceparallax] 28/9/2007 14:20

What IS Mr Preston doing - seems to be dragging out his sells as if trying to grab maximum Market attention and thus cause a drop.

[rambutan2] 25/9/2007 16:30

prob used it to buy the mrs a treat. Or suddenly found himself short of readies and with an unexpected bill to pay.

If he continues to sell then i'll start to take more notice.

[suesean1] 25/9/2007 09:36

Ram
What do you think about the news today? 11k.

[lgw] 24/9/2007 14:38

yes tortoise slow but sure to get to the finish line.
This is the interesting bit for me!
"Harry Rosen, Phosphagenics' President and CEO, said: "We have prioritised
oxycodone over morphine in our pain management pipeline as we are in commercial
discussions with several companies.
These companies' commercial interests are focused on the licence of a
transdermal pain product containing oxycodone."

PSG already commecialising transdermal oxycodone product! perhaps not so long to wait.
PS sign up for news alerts on PSG website works for me.

[spaceparallax] 24/9/2007 10:07

The newsflow continues. Progress is, by necessity, slow but solid.

[donaferentes] 20/9/2007 12:34

There NOMAD needs to give them a boot up the bottom - not the first time London has been left out of the Compnay's thinking. For example, London shareholders were simply omitted from the opportunity to investint he last fund-raising.

However, good news re the above information. They do not seem to have put a foot wrong so far. And you cannot hold these things to a strict timetable. So value will out eventually.

20p by next May - looks very nice, but not counting on it.

[suesean1] 20/9/2007 11:22

Rambutan,Thanks.

Had at least 20 google alerts on each news item from journals all over the world. Expected this drop and expect one more 1/2p, then a steady rise in the coming months. In for the long term, bit of pension i hope?

[rambutan2] 20/9/2007 09:53

Sean,

they are now investigating why the two pieces of news didn't get released in london.

[suesean1] 19/9/2007 10:57

If this news is not getting through to the public, how on earth can people make an investment.

Prediction 20p by next May.

[rambutan2] 19/9/2007 10:36

i emailed them about the first one but have had no reply and not chased it up. however, have been having probs with my email recently. will try again.

[suesean1] 19/9/2007 10:30

Hi Ram,

Why no RNS issued about these two bits of news.

[rambutan2] 19/9/2007 10:19

hi sean,

it's all looking good for psg.

[suesean1] 19/9/2007 10:15

From the PSG web site


17 September 2007



Phosphagenics to conduct a Phase 1 transdermal oxycodone clinical trial







Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that, following successful preclinical studies, it plans to undertake a Phase 1 transdermal oxycodone clinical trial aimed at providing chronic pain sufferers with a sustained-release pain management product.



Phosphagenics has submitted all necessary documents for approval of the trial, which is to be conducted at CMAX – an independent clinical research organisation located at the Royal Adelaide Hospital. The trial, which will be in up to 30 healthy volunteers, will evaluate the tolerability and safety of the novel transdermal oxycodone. The trial will begin once approval has been received, which is expected within the next six weeks.



The Company is working towards becoming the first to provide chronic pain sufferers with a patch that will provide sustained-release of oxycodone into the bloodstream. Previous clinical trials have demonstrated that Phosphagenics' patented technologies can effectively deliver opiates through the skin without causing any disruption or irritation.



Harry Rosen, Phosphagenics' President and CEO, said: "We have prioritised oxycodone over morphine in our pain management pipeline as we are in commercial discussions with several companies.



"These companies' commercial interests are focused on the licence of a transdermal pain product containing oxycodone."



Dr Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "Our objective is to address a large unmet need by using our technology to deliver oxycodone in a sustained-release formulation to treat pain beyond a 24 hour period."



Oxycodone, currently administered in tablet or intravenous form, in an eight to 12 hour formulation, is more potent than morphine with fewer adverse effects and its worldwide sales exceed $US 1 billion annually



Rambutan, are you still about?

Sean

[spaceparallax] 14/9/2007 13:32

Sus,

Thanks for the news.

[suesean1] 14/9/2007 12:04

Why no RNS about this? I have had at least 20 google alerts.
News Releases




12 September 2007



Phosphagenics to commence Phase 2 TPM/Insulin cinical trial






Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has received approval to commence a Phase 2 clinical trial of its proprietary transdermal insulin, TPM/Insulin.



The Phase 2 trial, to commence this month, will be single-blinded, placebo controlled, three way cross-over and randomised in up to 60 patients, with the endpoint of assessing the efficacy of TPM/Insulin in patients with type 1 and type 2 diabetes.



The trial, which will be conducted by CMAX at The Royal Adelaide Hospital under the guidance and supervision of Dr Sepehr Shakib, Director, Department of Clinical Pharmacology, Royal Adelaide Hospital and Associate Professor William Hsu of the Joslin Diabetes Centre, Harvard Medical School, is expected to be completed in the first half of 2008.



Dr Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "We are excited to reach this milestone and advance our technology for the transdermal delivery of insulin to Phase 2 trials.



"Our Phase 1b trial, conducted by CMAX at the Royal Adelaide Hospital, showed that our TPM/Insulin formulation safely penetrated through human skin and delivered insulin into the blood stream over a sustained period of time without adverse reactions.



"Phosphagenics' aim is to provide a safe and effective transdermal insulin to treat diabetes," she said

[spaceparallax] 08/8/2007 14:32

Agreed, very positive - one more solid step towards the pot of gold.

[lbo] 08/8/2007 11:14

Very positve news